Arthneeti

Marksans Pharma Q1 FY27 Share Price & Earnings Call Analysis

₹315.35+3.33% today
Market cap
₹14,291 Cr
P/E
27.66
ROE
15.17%
PEG
1.73
Price to sales
4.51
Debt to equity
0.11
52W high / low
₹348 / ₹157
Sales growth (5Y)
16.48%
EBITDA margin
22.50%
Net profit margin
14.18%
Promoter holding
43.87%
Sales (last year)
₹3,172 Cr

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Guidance scorecard · Q1 FY27 call

What Marksans Pharma Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#66of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookRising

RevenueQ1 FY27 call

10–20%
  • Management projects 15%-20% revenue growth for FY27, with some participants considering this conservative, suggesting 20%-25% could be achievable.
  • The company aims to double its revenue from INR3,000 crores within the next five years, indicating a strong growth trajectory.
  • In the U.S., the immediate goal is to reach $300 million in revenue, with a longer-term outlook towards $400 million in about five years.
  • Europe is targeted as a significant growth area with plans to expand into multiple countries through acquisitions, expecting about INR1,000 crores revenue from Europe within five years.
  • Organic growth is strong, especially in UK and Europe, with 50%+ year-on-year growth reported recently in the UK market.

2 more points from Marksans Pharma Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Marksans Pharma Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Marksans Pharma is exploring manufacturing capacity expansion with plans for potentially another unit in India within 1-2 years to meet 3-5 year growth goals, but no concrete plans finalized yet.
  • The company is actively seeking inorganic growth opportunities and acquisitions, especially in Europe, to expand its footprint. They have done smaller deals in Europe (Netherlands, Germany) but plan more acquisitions as part of growth strategy.
  • Management is conservative with cash usage, focusing on safe, high-return investments primarily in acquisitions rather than financial instruments.

2 more points from Marksans Pharma Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Marksans Pharma Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Rising
  • The order book remains strong, indicating healthy demand.
  • Growth contributions are expected from multiple geographies, including the U.S., Europe, Australia, and other subsidiaries.
  • The company anticipates continuing growth momentum across all markets in the current financial year.

2 more points from Marksans Pharma Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Marksans Pharma Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Marksans Pharma Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Marksans Pharma Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Marksans Pharma Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +486500531586560591642682708620720754856
Expenses +376398417453450462495543582520576594661
Operating Profit110102114133110128147139127100144161195
OPM %23%20%21%23%20%22%23%20%18%16%20%21%23%
Other Income +11101951715-028156222035
Interest2223533336666
Depreciation14141822212020212323272424
Profit before tax1049711411310012012514311677133151200
Tax %21%27%26%26%23%26%22%27%22%24%26%25%25%
Net Profit +83708483788998105915899114149
EPS in Rs1.811.521.841.841.731.962.132.312.001.292.172.503.27

Financials of Marksans Pharma Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +7978937679131,0001,1341,3761,4911,8522,1772,6232,951
Expenses +6127577228348689421,0371,2321,5131,7192,0942,350
Operating Profit1851364578132192340259340459529601
OPM %23%15%6%9%13%17%25%17%18%21%20%20%
Other Income +39785074259507083
Interest1610710109889111224
Depreciation162830272327364552748399
Profit before tax1561071550104157302248338424504561
Tax %28%23%24%28%23%23%21%25%21%26%24%25%
Net Profit +11283113680121239187265315383420
EPS in Rs2.671.920.220.801.872.955.764.515.886.928.409.22
Dividend Payout %4%21%23%6%3%3%4%6%9%9%10%0%

Financials of Marksans Pharma Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital414141414141414145454545
Reserves3264013924305025958461,1611,7002,0202,4222,978
Borrowings +1011001101181003034111123244322343
Other Liabilities +207180209142160236307323322372451494
Total Liabilities6767227527318029021,2281,6362,1902,6813,2403,861
Fixed Assets +1662702672792703033094284867769821,088
CWIP0000001231092715
Investments0000000012710
Other Assets +5104524844515335999071,2051,6941,8692,2302,758
Total Assets6767227527318029021,2281,6362,1902,6813,2403,861

Financials of Marksans Pharma Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1553114502723317999237230207458
Cash from Investing Activity +-33-123-21-39-13-60-45-84-259-141-49-248
Cash from Financing Activity +17-58-33-21-114-1580198-69-65-71
Net Cash Flow138-150-1015-760118941762193139
Free Cash Flow118-101-141114174133531842235329
CFO/OP108%43%31%73%41%134%67%66%88%77%63%100%

Financials of Marksans Pharma Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days8489118716478729782767580
Inventory Days107120151152215155248216192217270278
Days Payable888512954787110310291949896
Cash Conversion Cycle103124140169202163217211183199247261
Working Capital Days175977709787104121122129142149
ROCE %44%23%4%10%18%25%38%23%22%21%20%19%

Guidance history

How Marksans Pharma Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlanned—Rising
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →20–40%FlatPlanned—Rising
Q2 FY26 call →20–40%Up 0–2%Planned—Rising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

91out of 100

Momentum score · price trend

91 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+71.7%90%
Last 6 months+70.8%93%
Last 3 months+21.9%88%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Marksans Pharma Ltd: 0.4 × 90 + 0.4 × 93 + 0.2 × 88 = 91.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Marksans Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd